Express and Express FP modified live IBR, BVD Types 1 and 2, PI3 and BRSV vaccines, have received USDA approval for use in whole-herd vaccination programs. The whole-herd option greatly improves flexibility in vaccinating a pregnant cow and nursing calf provided the cow was vaccinated with Express FP prior to breeding.
To receive the new approval from USDA, Boehringer Ingelheim Vetmedica, maker of Express and Express FP vaccines, conducted extensive real-world safety studies involving more than 3,200 beef cows and calves in commercial cow/calf herds. The results demonstrated no difference in the number of fetal losses from animals vaccinated prior to and during pregnancy with Express FP vs. animals vaccinated with only Lepto during pregnancy. There were no fetal losses due to IBR or BVD viruses. Additional testing on newborns from cows that had been vaccinated during pregnancy also showed no detectable risk of vaccine virus being passed to the fetus.
Previous safety studies have demonstrated that calves vaccinated with Express did not shed the IBR, BVD Type 1 or BVD Type 2 virus components in the vaccine. This new round of studies provides another layer of assurance, demonstrating that even if previously vaccinated pregnant cows were to be exposed to the vaccine virus through a nursing calf that had been vaccinated, it would pose no significant risk to the developing fetus, says Dr. Carol Rinehart, PhD, bovine vaccines manager for the company.
"Our past research has proven Express FP vaccine has the industry's best efficacy record in protecting unborn calves from persistent BVD infection," says Dr. Rinehart, lead investigator on the new safety trials. "Now, this new round of research demonstrates Express FP also offers a high assurance of safety to go along with that effectiveness."
Source: Boehringer Ingelheim press release